Lysyl Oxidases Expression and Breast Cancer Progression: A Bioinformatic Analysis.
bioinformatics
breast cancer
gene expression
immune infiltration
lysyl oxidase
pharmacological inhibitors
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
02
2022
accepted:
30
05
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
9
7
2022
Statut:
epublish
Résumé
LOX (Lysyl oxidase) and LOX like 1-4 (LOXL1-4) are amine oxidases that catalyse the cross-linking of elastin and collagen in the extracellular matrix (ECM). This activity can facilitate cell migration and the formation of metastases. Consequently, inhibition of these enzymes and, in particular of LOXL2, has been suggested as a therapeutic strategy to prevent breast cancer metastasis. Although medicinal chemistry studies have struggled to specifically inhibit LOXL2, the importance of selectivity in this context is not clear. To explore the role of each LOX in breast cancer and consequently their potential as biomarkers or therapeutic targets, a bioinformatic-based approach was followed. The expression profile of
Identifiants
pubmed: 35800439
doi: 10.3389/fphar.2022.883998
pii: 883998
pmc: PMC9254715
doi:
Types de publication
Journal Article
Langues
eng
Pagination
883998Informations de copyright
Copyright © 2022 Ramos, Ferreira, Fernandes and Saraiva.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Antioxidants (Basel). 2021 Feb 19;10(2):
pubmed: 33669630
Cancer Res. 2007 May 1;67(9):4123-9
pubmed: 17456585
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Cancer Res. 2002 Aug 1;62(15):4478-83
pubmed: 12154058
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Bonekey Rep. 2012 May 02;1:80
pubmed: 27127624
EMBO Mol Med. 2011 Sep;3(9):528-44
pubmed: 21732535
Nature. 2015 Jun 4;522(7554):106-110
pubmed: 26017313
Am J Clin Nutr. 1998 May;67(5 Suppl):996S-1002S
pubmed: 9587142
Cancer Res. 2016 Jan 15;76(2):188-92
pubmed: 26732355
Cancer Res. 2017 Nov 1;77(21):5846-5859
pubmed: 28720577
Med Sci (Basel). 2020 Mar 23;8(1):
pubmed: 32210163
Breast Cancer Res Treat. 2013 Aug;141(1):89-99
pubmed: 23933800
Cell Death Differ. 2020 Nov;27(11):3021-3036
pubmed: 32424143
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Elife. 2017 Nov 13;6:
pubmed: 29130882
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16369-74
pubmed: 21911388
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Theranostics. 2020 Jul 9;10(19):8494-8512
pubmed: 32754259
Cell Death Differ. 2019 Nov;26(11):2237-2252
pubmed: 30728460
Cancers (Basel). 2020 Dec 29;13(1):
pubmed: 33383846
Cells. 2021 Jan 23;10(2):
pubmed: 33498711
Nat Commun. 2020 May 15;11(1):2416
pubmed: 32415208
Clin Cancer Res. 2016 Sep 1;22(17):4491-504
pubmed: 27029493
Oncotarget. 2017 Feb 14;8(7):11977-11989
pubmed: 28060764